Impact of Statin Treatment on Strut Coverage after Drug-Eluting Stent Implantation
2
조회
0
다운로드
2
인용
0
참고문헌
키워드
초록
Purpose: To evaluate the effect of statin treatment on strut coverage after drug-eluting stent (DES) implantation. Materials and Methods: In this study, 60 patientswere randomly assigned to undergo sirolimus-eluting stent (SES) or biolimus-eluting stent (BES) implantation, after which patients were randomly treated with pitavastatin 2 mg or pravastatin 20 mg for 6 months. The degree of strut coveragewas assessed by 6-month follow-up optical coherence tomography, which was performed in 52 DES-implanted patients. Results: The percentages of uncovered struts were 19.4±14.7% in pitavastatin-treated patients (n=25) and 19.1±15.2% in pravastatin-treated patients (n=27; p=0.927). A lower percentage of uncovered struts was significantly correlated with a lower follow-up low-density lipoprotein (LDL) cholesterol level (r=0.486; p=0.009) and a greater decline of the LDL cholesterollevel (r=-0.456; p=0.015) in SES-implanted patients, but not in BES-implantedpatients. In SES-implanted patients, the percentage of uncovered struts was significantly lower among those with LDL cholesterol levels of less than 70 mg/dL after 6 months of follow-up (p=0.025), but no significant difference in this variable according to the follow-up LDL cholesterol level was noted among BES-implanted patients (p=0.971). Conclusion: Lower follow-up LDL cholesterol levels,especially those less than 70 mg/dL, might have a protective effect against delayedstrut coverage after DES implantation. This vascular healing effect of lower LDL cholesterol levels could differ according to the DES type.
Abstract
Purpose: To evaluate the effect of statin treatment on strut coverage after drug-eluting stent (DES) implantation. Materials and Methods: In this study, 60 patientswere randomly assigned to undergo sirolimus-eluting stent (SES) or biolimus-eluting stent (BES) implantation, after which patients were randomly treated with pitavastatin 2 mg or pravastatin 20 mg for 6 months. The degree of strut coveragewas assessed by 6-month follow-up optical coherence tomography, which was performed in 52 DES-implanted patients. Results: The percentages of uncovered struts were 19.4±14.7% in pitavastatin-treated patients (n=25) and 19.1±15.2% in pravastatin-treated patients (n=27; p=0.927). A lower percentage of uncovered struts was significantly correlated with a lower follow-up low-density lipoprotein (LDL) cholesterol level (r=0.486; p=0.009) and a greater decline of the LDL cholesterollevel (r=-0.456; p=0.015) in SES-implanted patients, but not in BES-implantedpatients. In SES-implanted patients, the percentage of uncovered struts was significantly lower among those with LDL cholesterol levels of less than 70 mg/dL after 6 months of follow-up (p=0.025), but no significant difference in this variable according to the follow-up LDL cholesterol level was noted among BES-implanted patients (p=0.971). Conclusion: Lower follow-up LDL cholesterol levels,especially those less than 70 mg/dL, might have a protective effect against delayedstrut coverage after DES implantation. This vascular healing effect of lower LDL cholesterol levels could differ according to the DES type.
참고문헌 (33)
- Farb A, "Pathological mechaacute nisms of fatal late coronary stent thrombosis in humans", Circulation, 108, pp.1701~1706 (2003)
- Finn AV, "Pathological correlates of late drug-eluting stent thrombosis: strut coverage as a marker of endothelialization", Circulation, 115, pp.2435~2441 (2007)
- Guagliumi G, "Examination of the in vivo mechanisms of late drug-eluting stent thrombosis: findings from optical coherence tomography and intravascular ultrasound imaging", JACC Cardiovasc Interv, 5, pp.12~20 (2012)
- Won H, "Optical coherence tomography derived cut-off value of uncovered stent struts to predict adverse clinical outcomes after drug-eluting stent implantation", Int J Cardiovasc Imaging, 29, pp.1255~1263 (2013)
- Prati F, "Expert review document on methodology, terminology, and clinical applications of optical coherence tomography: physical principles, methodology of image acquisition, and clinical application for assessment of coronary arteries and atherosclerosis", Eur Heart J, 31, pp.401~415 (2010)
- 이승률, "Stent Evaluation with Optical Coherence Tomography", Yonsei Medical Journal, 54(5), pp.1075~1083 (2013), 연세대학교의과대학[DOI]
- Kim JS, "Optical coherence tomography evaluation of zotarolimus-eluting stents at 9-month follow-up: comparison with sirolimus-eluting stents", Heart, 95, pp.1907~1912 (2009)
- Takano M, "Evaluation by optical coherence tomography of neointimal coverage of sirolimus-eluting stent three months after implantation", Am J Cardiol, 99, pp.1033~1038 (2007)
- Kim JS, "Different patterns of neointimal coverage between acute coronary syndrome and stable angina after various types of drug-eluting stents implantation; 9-month follow-up optical coherence tomography study", Int J Cardiol, 146, pp.341~346 (2011)
- Kubo T, "Comparison of vascular response after sirolimus-eluting stent implantation between patients with unstable and stable angina pectoris: a serial optical coherence tomography study", JACC Cardiovasc Imaging, 1, pp.475~484 (2008)
- Mihos CG, "The pleiotropic effects of the hydroxy-methyl-glutaryl-CoA reductase inhibitors in cardiovascular disease: a comprehensive review", Cardiol Rev, 18, pp.298~304 (2010)
- Indolfi C, "Effects of hydroxymethylglutaryl coenzyme A reductase inhibitor simvastatin on smooth muscle cell proliferation in vitro and neointimal formation in vivo after vascular injury", J Am Coll Cardiol, 35, pp.214~221 (2000)
- Bellosta S, "Direct vascular effects of HMG-CoA reductase inhibitors", Atherosclerosis, 137(Suppl), pp.S101~S109 (1998)
- Wang TJ, "Atorvastatin accelerates both neointimal coverage and re-endothelialization after sirolimus-eluting stent implantation in a porcine model: new findings from optical coherence tomography and pathology", Circ J, 76, pp.2561~2571 (2012)
- Jaschke B, "Local statin therapy differentially interferes with smooth mus cle and endothelial cell proliferation and reduces neointima on a drug-eluting stent platform", Cardiovasc Res, 68, pp.483~492 (2005)
- Kim BK, "Randomised comparison of strut coverage between Nobori biolimus-eluting and sirolimus-eluting stents: an optical coherence tomography analysis", EuroIntervention, 9, pp.1389~1397 (2014)
- Tanigawa J, "The influence of strut thickness and cell design on immediate apposition of drug-eluting stents assessed by optical coherence tomography", Int J Cardiol, 134, pp.180~188 (2009)
- Davlouros PA, "An optical coherence tomography study of two new generation stents with biodegradable polymer carrier, eluting paclitaxel vs. biolimus-A9", Int J Cardiol, 157, pp.341~346 (2012)
- Kume T, "Assessment of coronary arterial thrombus by optical coherence tomography", Am J Cardiol, 97, pp.1713~1717 (2006)
- Doran H, "Estimating the multilevel Rasch model: with the lme4 package", J Stat Softw, 20, pp.1~18 (2007)
- Kim BK, "Major determinants for the uncovered stent struts on optical coherence tomography after drug-eluting stent implantation", Int J Cardiovasc Imaging, 28, pp.705~714 (2012)
- Kim BK, "Impact of preprocedural high-sensitivity C-reactive protein levels on uncovered stent struts: an optical coherence tomography study after drug-eluting stent implantation", Clin Cardiol, 34, pp.97~101 (2011)
- Ishigami K, "Long-term follow-up of neointimal coverage of sirolimus-eluting stents--evaluation with optical coherence tomography", Circ J, 73, pp.2300~2307 (2009)
- Fukuda D, "Fluvastatin accelerates re-endothelialization impaired by local sirolimus treatment", Eur J Pharmacol, 612, pp.87~92 (2009)
- Wolfrum S, "Endothelium-dependent effects of statins", Arterioscler Thromb Vasc Biol, 23, pp.729~736 (2003)
- Werner N, "Bone marrow-derived progenitor cells modulate vascular reendothelialization and neointimal formation: effect of 3-hydroxy-3-methylglutaryl coenzyme a reductase inhibition", Arterioscler Thromb Vasc Biol, 22, pp.1567~1572 (2002)
- Walter DH, "Effects of statins on endothelium and their contribution to neovascularization by mobilization of endothelial progenitor cells", Coron Artery Dis, 15, pp.235~242 (2004)
- Sakamoto T, "Usefulness of hydrophilic vs lipophilic statins after acute myocardial infarction: subanalysis of MUSASHI-AMI", Circ J, 71, pp.1348~1353 (2007)
- Satoh K, "Lipophilic HMG-CoA reductase inhibitors increase myocardial stunning in dogs", J Cardiovasc Pharmacol, 35, pp.256~262 (2000)
- Saku K, "PATROL Trial Investigators. Randomized head-to-head comparison of pitavastatin, atorvastatin, and rosuvastatin for safety and efficacy (quantity and quality of LDL): the PATROL trial", Circ J, 75, pp.1493~1505 (2011)
- Hayashi T, "Pitavastatin: efficacy and safety in intensive lipid lowering", Expert Opin Pharmacother, 8, pp.2315~2327 (2007)
- Chevalier B, "Randomized comparison of the Nobori Biolimus A9-eluting coronary stent with the Taxus Liberté paclitaxel-eluting coronary stent in patients with stenosis in native coronary arteries: the NOBORI 1 trial--Phase 2", Circ Cardiovasc Interv, 2, pp.188~195 (2009)
- Ostojic M, "First clinical comparison of Nobori -Biolimus A9 eluting stents with Cypher- Sirolimus eluting stents: Nobori Core nine months angiographic and one year clinical outcomes", EuroIntervention, 3, pp.574~579 (2008)